Drug | Mode of action | IMID licensed indication(s) | Mode of administration | Date of last SmPC update at time of search |
csDMARDs | ||||
Azathioprine | Purine synthesis inhibitor | Crohn’s, UC, RA | Oral | 03 December 2019 |
Ciclosporin | Calcineurin inhibitor | UC, RA, PsO, atopic dermatitis | Oral | 10 March 2020 |
Cladribine | Purine analogue | MS | Oral | 21 January 2020 |
Interferon beta | Unknown | MS | SC, IM | 23 October 2019 |
Leflunomide | Pyrimidine synthesis inhibitor | RA, PsA | Oral | 15 August 2017 |
Methotrexate | Dihydrofolate reductase inhibitor | Crohn’s, RA, PsO | Oral, SC, IM | 23 January 2020 |
Mycophenolate mofetil | Inosine-5′-monophosphate dehydrogenase inhibitor | Nil IMID | Oral | 25 November 2020 |
Sulfasalazine | Unknown | Crohn’s, UC, RA | Oral | 15 October 2019 |
Teriflunomide | Dihydro-orotate dehydrogenase inhibitor | MS | Oral | 18 September 2020 |
tsDMARDs | ||||
Baricitinib | JAK1 and JAK2; limited inhibition of TYK2) | RA | Oral | 26 November 2019 |
Filgotinib | JAK1 | RA | Oral | 24 September 2020 |
Tofacitinib | JAK3 and JAK1; some affinity for JAK2; limited affinity for TYK2 | RA | Oral | 06 February 2020 |
Upadacitinib | JAK1 | RA | Oral | 01 April 2020 |
Fingolimod | Sphingosine 1-phosphate receptor modulator | MS | Oral | 16 January 2020 |
Siponimod | Sphingosine 1-phosphate receptor modulator | MS | Oral | 24 April 2020 |
bDMARDs | ||||
Cytokine/enzyme-targeted | ||||
Adalimumab | TNFα inhibitor | Crohn’s, UC, RA, PsO, axSpA, nr-axSpA | SC | 04 September 2020 |
Anakinra | IL-1 receptor antagonist | RA, CAPS, Still’s | SC | 28 May 2020 |
Canakinumab | IL-1β inhibitor | Gout, autoinflammatory syndromes, Still’s | SC | 13 March 2020 |
Certolizumab pegol | TNFα inhibitor | RA, PsO, axSpA, PsA | SC | 12 August 2020 |
Dupilumab | IL-4 receptor antagonist | Mod-severe atopic dermatitis, severe asthma | SC | 26 September 2017 |
Eculizumab | C5 complement inhibitor | PNH | IV | 29 June 2020 |
Etanercept | TNFα inhibitor | RA, PsO, PsA, AS, nr-axSpA | SC | 14 September 2020 |
Golimumab | TNFα inhibitor | UC, RA, PsO, AS, nr-axSpA | SC, IV | 12 May 2020 |
Guselkumab | IL-23 inhibitor | PsO | SC, IV | 29 June 2020 |
Infliximab | TNFα inhibitor | Crohn’s, UC, RA, AS, PsA, PsO | SC, IV | 28 October 2019 |
Ixekizumab | IL-17A inhibitor | PsO, PsA | SC | 16 July 2020 |
Mitoxantrone | Type II topoisomerase inhibitor | nil IMID | IV | 07 January 2020 |
Ravulizumab | C5 complement inhibitor | PNH | IV | 28 September 2020 |
Sarilumab | IL-6 receptor antagonist | RA | SC | 23 June 2017 |
Secukinumab | IL-17A inhibitor | AS, PsA, PsO | SC | 19 August 2020 |
Tocilizumab | IL-6 receptor antagonist | RA, GCA | IV | 02 September 2020 |
Ustekinumab | IL-12/23 inhibitor | Crohn’s, UC, PsO, PsA | SC | 27 February 2020 |
Cell-targeted | ||||
Abatacept | CTLA-4 inhibitor | RA, PsA | SC, IV | 10 June 2020 |
Alemtuzumab | CD52 antagonist | MS | IV | 16 September 2020 |
Belimumab | B-cell activating factor | SLE | IV | 28 September 2020 |
Natalizumab | α4β1 integrin inhibitor | MS | IV | 12 May 2020 |
Ocrelizumab | CD20 inhibitor | MS | IV | 01 June 2020 |
Rituximab | CD20 inhibitor | RA, autoimmune vasculitis, pemphigus vulgaris | IV | 08 April 2020 |
Vedolizumab | α4β7 integrin inhibitor | Crohn’s, UC | SC, IV | 15 May 2020 |
UC= ulcerative colitis; PsO= psoriasis; PsA= psoriatic arthritis; MS= multiple sclerosis; CAPS= cryopyrin-associated periodic syndrome; AxSpA= axial spondyloarthritis; SLE= systemic lupus erythematosus
IMID, immune-mediated inflammatory disease; JAK, Janus kinase; RA, rheumatoid arthritis; TNF, tumour necrosis factor.